MIF Antagonist, ISO-1

Product NameMIF Antagonist, ISO-1
CAS478336-92-4
MFC12H13NO4
MW235.24
EINECS
MOL File478336-92-4.mol

Chemical Properties

Melting point	114 °C
Boiling point	365.0±48.0 °C(Predicted)
Density	1.30±0.1 g/cm3(Predicted)
storage temp.	Keep in dark place,Sealed in dry,Store in freezer, under -20°C
solubility	Soluble in DMSO.
pka	9.22±0.30(Predicted)
form	Light yellow crystalline solid.
color	Off-white
Sensitive	Light Sensitive
Stability	Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
InChI	InChI=1S/C12H13NO4/c1-16-12(15)7-10-6-11(13-17-10)8-2-4-9(14)5-3-8/h2-5,10,14H,6-7H2,1H3
InChIKey	AIXMJTYHQHQJLU-UHFFFAOYSA-N
SMILES	O1C(CC(OC)=O)CC(C2=CC=C(O)C=C2)=N1

Safety Information

WGK Germany	WGK 1
Storage Class	10 - Combustible liquids

Usage And Synthesis

Description

ISO-1 (478336-92-4) is an antagonist of macrophage migration inhibitory factor (MIF, a pro-inflammatory cytokine). Displays anti-inflammatory activity. Increases survival in severe sepsis.1 Inhibits airway remodeling in mouse asthma model.2 ISO-1 also blocks MIF-induced autophagy.3Active in cellular and mouse models.

Uses

MIF Antagonist, ISO-1 inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC50 = 7 μM for D-dopachrome tautomerase) and suppresses the production of TNFα, PGE2 and COX-2 in human monocytes and arachidonic acid in RAW 264.7 macrophages. MIF Antagonist, ISO-1 has been shown to exhibit antidiabetogenic properties in immunoinflammatory diabetic mouse model.

in vivo

ISO-1 (injected intraperitoneally; 3.5-35 mg/kg; twice daily; 2 weeks) improves the survival rate from lethal endotoxemia and shows the anti-inflammatory effect^[2]. ISO-1 (intraperitoneal injection; 35 mg/kg; twice daily; 3 days) causes a significant reduction in average implant size and decreases Flk1 expression in implants^[3].

Animal Model:	C57Bl/6 MIF^+/+ and MIF^–/– mice^[2]
Dosage:	3.5-35 mg/kg
Administration:	Injected intraperitoneally; 3.5-35 mg/kg; twice a day ; 2 weeks
Result:	Was protective against lethal sepsis.

Animal Model:	Female C57BL/6-Tg(ACTB-EGFP)1Osb/J mice^[3]
Dosage:	35 mg/kg
Administration:	Intraperitoneal injection; 35 mg/kg; twice daily; 3 days
Result:	Reduced average endometriotic implant size.

storage

Store at +4°C

References

[1] YOUSEF AL-ABED. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis.[J]. The Journal of Biological Chemistry, 2005, 280 44: 36541-36544. DOI:10.1074/jbc.c500243200
[2] PEI-FEN CHEN. ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma.[J]. Molecular Medicine, 2010, 16 9-10: 400-408. DOI:10.2119/molmed.2009.00128
[3] YUNG-CHUN CHUANG. Macrophage migration inhibitory factor induces autophagy via reactive oxygen species generation.[J]. ACS Applied Bio Materials, 2012: e37613. DOI:10.1371/journal.pone.0037613

MIF Antagonist, ISO-1 Supplier

MIF Antagonist, ISO-1 manufacturers

Related Product Information

Send Inquriy